ArticleClinics in orthopedic surgery2026
Early Denosumab Administration after Distal Radius Fractures in Postmenopausal Women: A Retrospective Comparison with Zoledronic Acid.
Article in Clinics in orthopedic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the effects of early administration of denosumab (DE) on bone healing and bone mineral density (BMD) in postmenopausal women with osteoporotic distal radius fractures treated with volar plate fixation. Although the safety of early bisphosphonate use has been well established, clinical evidence regarding the early use of DE remains limited. Methods: A retrospective study was conducted on postmenopausal women aged 55 years or older who underwent volar plate fixation for osteoporotic distal radius fractures between April 2018 and July 2022. Participants were treated with either intravenous zoledronic acid (ZA group) or subcutaneous DE (DE group). BMD and bone turnover markers (C-terminal telopeptide of type 1 collagen [CTX-1] and osteocalcin) were measured preoperatively, at 3 months, and 1 year after surgery. Radiographic outcomes, range of motion (ROM), and Disabilities of the Arm, Shoulder, and Hand (DASH) scores were evaluated at 1 year. Additionally, patient satisfaction was assessed through a telephone survey. Results: A total of 65 patients were included (35 in the ZA group, 30 in the DE group). Both groups showed significant improvements in lumbar spine and femoral neck BMD T-scores at 1 year, with no significant difference between the groups. Bone resorption marker CTX-1 decreased significantly in both groups, with a significant intergroup difference at 1 year ( Conclusions: Early administration of DE after distal radius fracture surgery is safe and does not impair bone healing. Given the higher patient satisfaction and lower rate of adverse events, DE may be a favorable option for early osteoporosis management in the postoperative setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.